Rapport Therapeutics, Inc.
RAPPRapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders.
Earnings
Next report
Aug 6, 2026 (in a month)Revenue estimate$2.2M
EPS estimate-$0.96
Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders. The company utilizes a proprietary RAP technology platform to target receptor-associated proteins (RAPs), enabling neuroanatomical specificity that aims to reduce the side effects common in traditional neuroscience drugs.
Competitive position
A clinical-stage innovator using a differentiated RAP-based platform to achieve regional brain specificity for validated CNS targets.
GeographiesUnited States, Global
Customer segmentsPatients, Healthcare providers
Business modelR&D-stage biotechnology, IP licensing
SuppliersContract Manufacturing Organizations (CMOs), Academic research institutions, Specialized laboratory equipment suppliers
CustomersClinical trial participants, Pharmaceutical distributors (future), Strategic commercial partners
Questions, answered.
- What is Rapport Therapeutics, Inc.'s market cap?
- Rapport Therapeutics, Inc. (RAPP) has a market capitalization of $1.9B and trades on NASDAQ.
- Who are Rapport Therapeutics, Inc.'s competitors?
- Rapport Therapeutics, Inc.'s key competitors include Biohaven Ltd., Xenon Pharmaceuticals Inc., Praxis Precision Medicines, Inc., and others. These companies compete in similar markets and product categories.
- Who does Rapport Therapeutics, Inc. partner with?
- Rapport Therapeutics, Inc.'s notable partners include Janssen Pharmaceutical NV, NeuroPace, Inc., Third Rock Ventures, and others.
- Where is Rapport Therapeutics, Inc. headquartered?
- Rapport Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.